MA53487A - Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met - Google Patents

Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met

Info

Publication number
MA53487A
MA53487A MA053487A MA53487A MA53487A MA 53487 A MA53487 A MA 53487A MA 053487 A MA053487 A MA 053487A MA 53487 A MA53487 A MA 53487A MA 53487 A MA53487 A MA 53487A
Authority
MA
Morocco
Prior art keywords
tam
pyrazolo
kinase inhibitors
compounds used
pyridine compounds
Prior art date
Application number
MA053487A
Other languages
English (en)
Inventor
Shelley Allen
Patrick Barbour
Adam Cook
Joshua Dahlke
John Gaudino
Ronald Jay Hinklin
Ellen Laird
Oren T Mcnulty
Qian Zhao
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MA53487A publication Critical patent/MA53487A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA053487A 2018-08-30 2019-08-29 Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met MA53487A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862724829P 2018-08-30 2018-08-30
US201962858686P 2019-06-07 2019-06-07

Publications (1)

Publication Number Publication Date
MA53487A true MA53487A (fr) 2021-12-08

Family

ID=67928919

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053487A MA53487A (fr) 2018-08-30 2019-08-29 Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met

Country Status (25)

Country Link
US (3) US11104676B2 (fr)
EP (1) EP3843850B1 (fr)
JP (2) JP6970859B2 (fr)
KR (1) KR20210049898A (fr)
CN (1) CN112930215A (fr)
AU (3) AU2019330017B2 (fr)
BR (1) BR112021002722A2 (fr)
CA (1) CA3110502C (fr)
CL (1) CL2021000467A1 (fr)
CO (1) CO2021002651A2 (fr)
CR (1) CR20210098A (fr)
CU (1) CU20210015A7 (fr)
DO (1) DOP2021000038A (fr)
EC (1) ECSP21012498A (fr)
IL (1) IL281127B2 (fr)
MA (1) MA53487A (fr)
MX (1) MX2021001952A (fr)
NI (1) NI202100007A (fr)
PE (1) PE20211779A1 (fr)
PH (1) PH12021500017A1 (fr)
PY (1) PY1972250A (fr)
SG (1) SG11202101148UA (fr)
TW (1) TW202024071A (fr)
UY (1) UY38349A (fr)
WO (1) WO2020047184A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7442439B2 (ja) 2017-03-30 2024-03-04 アルベルト－ルートヴィヒ－ユニバーシティー フライブルク Ｋｄｍ４阻害剤
CN110857293B (zh) * 2018-08-24 2023-01-10 药捷安康(南京)科技股份有限公司 一种新型的喹啉衍生物抑制剂
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
AU2020342108B2 (en) 2019-09-06 2024-03-07 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof
EP4036086A1 (fr) * 2019-09-24 2022-08-03 Transthera Sciences (Nanjing), Inc. Dérivé hétérocyclique et utilisation associée
US12371428B2 (en) 2019-09-26 2025-07-29 Exelixis, Inc. Pyridone compounds and methods of use
WO2021176330A1 (fr) * 2020-03-03 2021-09-10 Array Biopharma Inc. Méthodes de traitement du cancer à l'aide de (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phényl)-3-(4-fluorophényl)-1-isopropyl-2,4-dioxo-1,2,3,4-tétrahydropyrimidine-5-carboxamide
CN113912628B (zh) * 2020-07-10 2023-05-02 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
US20250025451A1 (en) * 2021-04-09 2025-01-23 Celgene Corporation Treatment of cancer with kdm4 inhibitors
EP4332106A4 (fr) * 2021-06-22 2024-10-30 LG Chem, Ltd. Nouveau composé en tant qu'inhibiteur de protéine kinase
WO2023002360A1 (fr) 2021-07-22 2023-01-26 Pfizer Inc. Formes solides et formulations d'un inhibiteur de tam et de c-met kinases
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN115850301B (zh) * 2021-09-24 2024-11-15 中山医诺维申新药研发有限公司 吡唑酮类化合物及其组合物和用途
US20250032464A1 (en) * 2021-11-05 2025-01-30 Haihe Biopharma Co., Ltd. Solid dispersion, preparation method therefor, and solid formulation containing same
CN118159538A (zh) * 2021-11-05 2024-06-07 上海海和药物研究开发股份有限公司 含met受体酪氨酸激酶抑制剂的药物组合及应用
IL313548A (en) 2021-12-16 2024-08-01 Kinnate Biopharma Inc MET kinase inhibitors
AU2022424157A1 (en) * 2021-12-29 2024-07-18 Beijing Avistone Biotechnology Co., Ltd. Heteroaromatic nitrogen-oxide compound, preparation method therefor, and use thereof
JP2025502748A (ja) 2021-12-30 2025-01-28 バイオメア フュージョン，インコーポレイテッド Ｆｌｔ３の阻害剤としてのピラジン化合物
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN116768868B (zh) * 2023-08-15 2023-12-08 云南省药物研究所 一种哒嗪酮硫代衍生物及其制备方法和应用
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
CN118878515B (zh) * 2024-06-19 2025-10-28 河北科技大学 一种取代苯胺嘧啶类化合物及其制备方法和用途
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5368701B2 (ja) 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
CA2645137A1 (fr) * 2006-03-07 2007-09-13 James F. Blake Derives heterobicycliques de pyrazole et methodes d'utilisation
CN102816175B (zh) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
WO2013032797A2 (fr) * 2011-08-26 2013-03-07 New Hope R & D Bioscience, Inc. Composés oxétane-3,3-dicarboxamides et leurs procédés de fabrication et d'utilisation
US20130078252A1 (en) * 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
AU2012339640B2 (en) * 2011-11-14 2017-01-05 Ignyta, Inc. Uracil derivatives as AXL and c-MET kinase inhibitors
US10028956B2 (en) 2013-08-02 2018-07-24 Ignyta, Inc. Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agents
SG11201605207PA (en) * 2013-12-26 2016-07-28 Ignyta Inc Pyrazolo[1,5-a]pyridine derivatives and methods of their use
WO2016004272A1 (fr) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
KR101829998B1 (ko) 2015-11-04 2018-02-19 롬엔드하스전자재료코리아유한회사 착색 감광성 수지 조성물 및 이를 이용한 차광성 스페이서
AU2017241524B2 (en) * 2016-03-28 2021-07-08 Incyte Corporation Pyrrolotriazine compounds as TAM inhibitors
EP3490676A1 (fr) 2016-07-29 2019-06-05 Eli Lilly and Company Polythérapie à base de méréstinib et d'inhibiteurs anti-pd-l1 ou anti-pd-1 destinée à être utilisée dans le traitement du cancer
US20190185567A1 (en) 2016-08-01 2019-06-20 Ignyta, Inc. Combinations for the treatment of cancer
WO2018039275A1 (fr) 2016-08-24 2018-03-01 Ignyta, Inc. Combinaisons pour le traitement du cancer
JP2019536771A (ja) 2016-11-16 2019-12-19 イーライ リリー アンド カンパニー エクソン１４スキッピング変異またはエクソン１４スキッピング表現型を有する癌の治療
CN108250200A (zh) 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN111372925B (zh) 2017-11-24 2022-09-02 南京明德新药研发有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
US11247990B1 (en) 2017-12-07 2022-02-15 Array Biopharma Inc Bicyclic fused pyridine compounds as inhibitors of TAM kinases

Also Published As

Publication number Publication date
CR20210098A (es) 2021-07-01
SG11202101148UA (en) 2021-04-29
PY1972250A (es) 2022-04-12
KR20210049898A (ko) 2021-05-06
MX2021001952A (es) 2021-04-19
AU2019330017A1 (en) 2021-03-04
AU2019330017B2 (en) 2022-05-26
AU2022202946B2 (en) 2023-08-03
IL281127B2 (en) 2024-04-01
US20240174666A1 (en) 2024-05-30
JP2021527114A (ja) 2021-10-11
CU20210015A7 (es) 2021-10-12
AU2022202946A1 (en) 2022-05-26
AU2022221514A1 (en) 2022-09-22
CN112930215A (zh) 2021-06-08
AU2022221514B2 (en) 2023-11-02
CL2021000467A1 (es) 2021-10-22
JP2022009720A (ja) 2022-01-14
US20230011441A1 (en) 2023-01-12
DOP2021000038A (es) 2021-04-15
BR112021002722A2 (pt) 2021-08-10
PE20211779A1 (es) 2021-09-08
CA3110502A1 (fr) 2020-03-05
EP3843850B1 (fr) 2023-11-15
JP7337133B2 (ja) 2023-09-01
TW202024071A (zh) 2020-07-01
PH12021500017A1 (en) 2021-09-13
IL281127B1 (en) 2023-12-01
UY38349A (es) 2020-03-31
JP6970859B2 (ja) 2021-11-24
IL281127A (en) 2021-04-29
NI202100007A (es) 2021-06-22
US11780835B2 (en) 2023-10-10
CA3110502C (fr) 2023-10-03
EP3843850A1 (fr) 2021-07-07
ECSP21012498A (es) 2021-03-31
US11104676B2 (en) 2021-08-31
WO2020047184A1 (fr) 2020-03-05
CO2021002651A2 (es) 2021-03-08
US20200079770A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
MA53487A (fr) Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
MA49570A (fr) Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA52360A (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
CY1125460T1 (el) Ενωσεις ιμιδαζο [4,5-d]πυρρολο [2,3-β]πυριδινης ως αναστολεις κινασων janus
EP3997087A4 (fr) Composés bicycliques hétéroaromatiques fusionnés substitués utilisés en tant qu'inhibiteurs de kinase et leur utilisation
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
MA53726A (fr) Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
EP3877371A4 (fr) Dérivés d'imidazopyridine et dérivés d'aza-imidazopyridine utilisés comme inhibiteurs de la janus kinase 2 et utilisations associées
MA54551A (fr) Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine
MA52593A (fr) 1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1
MX386481B (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA46264A (fr) Dérivés pyrazolo[1,5-a]pyridine et leur utilisation en tant qu'agents de lutte antiparasitaire
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3706749A4 (fr) Composés macrocycliques en tant qu'inhibiteurs de kinase trk et leurs utilisations
MA49956A (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
SG11201907095UA (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
MA52940A (fr) Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine